Related Experiment Video
Updated: Feb 10, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Dientamoeba fragilis dominance in IBS and Blastocystis sp. in ulcerative colitis
Melis Cengiz1, Yunus Emre Beyhan2, Yusuf Kayar3
1Department of Parasitology, Faculty of Medicine, Van Yüzüncü Yıl University.
Abstract:
Intestinal diseases markedly impair quality of life, with irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn's disease (CD) representing major functional and inflammatory gastrointestinal disorders. This study aimed to determine the prevalence of Dientamoeba fragilis and other intestinal parasites in these conditions and to compare the diagnostic performance of conventional and molecular methods. A total of 80 stool samples were analyzed, including 60 from patients with IBS, UC, or CD and 20 from healthy controls. Samples were examined using direct microscopy, concentration techniques, trichrome staining (TS), and real-time polymerase chain reaction (qPCR), which was applied specifically for the detection of D. fragilis. Overall, parasites were detected in 60% of patients and 15% of controls. Infection rates were 33.3% in CD, 68.8% in UC, and 58.5% in IBS patients. D. fragilis was identified in 18.8% of UC and 22.0% of IBS cases, with significant differences observed between microscopy, TS, and qPCR in detection rates. Blastocystis sp. was found in 21.7% of patients and 5% of controls, with the highest prevalence in UC patients (37.5%). Other detected parasites included Iodamoeba bütschlii, Endolimax nana, Entamoeba coli, Giardia intestinalis, Chilomastix mesnili, Entamoeba spp., and Cystoisospora belli. While direct microscopy showed limited sensitivity, TS improved detection moderately, and qPCR provided the highest sensitivity for D. fragilis. These findings highlight the predominance of D. fragilis in IBS and Blastocystis sp. in UC and underscore the importance of molecular methods for accurate parasitological diagnosis.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Incomplete Dominance
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.